Teva’s €1bn euro debut a huge hit with investors
Teva Pharmaceutical Industries, the Israeli generic drug company, launched its first bond outside dollars on Thursday, raising €1bn in a sale that found exceptionally strong demand, with a €7bn order book.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts